Orthocell Ltd ( (AU:OCC) ) has issued an update.
Orthocell Limited has received regulatory approval from Brazil’s ANVISA for its dental regeneration product, Striate+, marking its first market authorization in Latin America. This approval is a strategic milestone for Orthocell, as Brazil represents a significant market opportunity and serves as a gateway for further expansion into Latin American countries. The approval follows the recent US FDA clearance for another product, Remplir, highlighting the company’s successful global commercialization efforts. With a strong balance sheet and a robust distribution partnership with BioHorizons, Orthocell is well-positioned to capitalize on the estimated US$735 million global market opportunity for Striate+, targeting a 20% market share.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company specializing in dental and tissue regeneration products. Their primary product, Striate+, is a resorbable collagen membrane used in dental bone and tissue regeneration applications. The company is focused on expanding its market presence globally, with a particular emphasis on the dental industry.
YTD Price Performance: -1.47%
Average Trading Volume: 1,525,695
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$340M
Find detailed analytics on OCC stock on TipRanks’ Stock Analysis page.